Currently, four anti-CD19 CAR-T therapies have been approved by the Food and Drug Administration (FDA) for the management of R/R large B-cell lymphoma (LBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) including: Axicabtagene Ciloleucel (Yescarta) [7], Brexucabtagene Autoleucel (Tecartus) [8], Lisocabtagene Marleucel (Breyanzi) [9], and Tisagenlecleucel (Kymriah) [10]. This evidence concerns the gene CD19 and mantle cell lymphoma.